SVA — Sinovac Biotech Cashflow Statement
0.000.00%
HealthcareMicro Cap
Annual cashflow statement for Sinovac Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 65.2 | 185 | 14,459 | 88.1 | -258 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 2.95 | 18.5 | 81.1 | 149 | -137 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -28.2 | 283 | 461 | -1,081 | 278 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 39.1 | 479 | 15,353 | -771 | 104 |
Capital Expenditures | -10.6 | -128 | -720 | -403 | -146 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -31.8 | -77.1 | -2,304 | -5,357 | -2,778 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -42.5 | -205 | -3,024 | -5,760 | -2,924 |
Financing Cash Flow Items | 1.48 | 558 | 4.32 | 26.1 | -316 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.74 | 593 | -1,897 | -241 | -76.1 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2.29 | 894 | 10,570 | -7,333 | -3,011 |